Article Text

SAT0337 Impact of organ involvement on patient-reported outcomes in patients with idiopathic inflammatory myopathies
  1. D Huscher1,
  2. K Albrecht1,
  3. J Richter2,
  4. J Henes3,
  5. T Alexander4,
  6. A Zink1,4
  1. 1Epidemiology, German Rheumatism Research Centre, Berlin
  2. 2Policlinic & Hiller Research Unit for Rheumatology, Medical Faculty, Heinrich-Heine-University Duesseldorf, University Clinic, Duesseldorf
  3. 3Department of Rheumatology and Clinical Immunology, Eberhard Karls-University of Tuebingen, Tuebingen
  4. 4Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany


Background Idiopathic inflammatory myopathies (IIM) are associated with considerable morbidity, primarily related to severe muscle weakness and visceral involvement, resulting in disability and impaired quality of life1. Results from the OMERACT Myositis Special Interest Group indicate that there is insufficient knowledge on patient-reported outcomes (PROs) in IIM2.

Objectives To analyse the association between organ involvement and PROs in IIM patients, taking the presence of autoantibodies into account.

Methods Data of IIM patients, recorded in the National Database of the German collaborative arthritis centres between 2007 and 2014, were analysed. Physician-reported data on myositis disease phenotypes, organ involvement and antibody status were linked with PROs on functional status (FFbH, range 0–100, 100 indicating full capability), and numerical rating scales (0–10) for pain, fatigue, general health, physical and emotional well-being and coping. Multivariable linear regression analysis was used to investigate the impact of phenotype, organ involvement and autoantibodies on PROs, adjusted for sex, age and disease duration.

Results A total of 142 IIM patients - 60 polymyositis (PM), 46 dermatomyositis (DM), 15 antisynthetase syndrome (ASS), 12 overlap (OL), 9 others - with mean disease duration of 7.4 years were included. 85% showed muscular, 36% skin involvement, 22% arthritis, 28% interstitial lung disease, 17% dysphagia and 9% cardiomyopathy. Visceral (lung, cardiac or gastrointestinal) manifestation was present in 46% (PM), 54% (DM), 100% (ASS), and 80% (overlap). While moderate to severe (4–10) fatigue was predominately reported in overlap (64%) and ASS (70%), pain was more frequent in overlap (55%) and emotional discomfort was reported most frequently in ASS (57%). For all PROs, worse outcomes were documented in patients with visceral manifestation. Myositis-specific autoantibodies, predominantly Anti-Jo1, were present in 63% of the patients, and were associated with more frequent visceral manifestation (73% vs. 46%), especially interstitial lung disease (50% vs. 15%), and arthritis (32% vs. 13%), but less skin involvement (26% vs. 49%). DM and PM subtypes showed almost identical coefficients for fatigue, physical well-being, general health and coping, while PM was associated with higher emotional strain. Pulmonary hypertension had a severe impact on pain, functional status and daily activities. Cardiomyopathy was associated with impaired general health, arthritis with poorer scores for coping, physical and emotional well-being.

Conclusions IIM patients with distinct subtypes differ considerably regarding the frequency of organ involvement and self-reported dimensions of disease burden. Anti-Jo1 positivity is associated with higher visceral organ involvement and arthritic manifestations and may therefore also indicate a higher patient-reported disease burden.


  1. Marie I. Curr Rheumatol Rep 2012;14:275–85.

  2. Regardt M et al. Report from OMERACT 12. J Rheumatol. 2015;42:2492–5.


Acknowledgements The database is funded by unconditional grants from the German Collaborative Arthritis Centres and from a consortium of 11 pharmaceutical companies to the German Academy for Continuing Medical Education in Rheumatology.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.